FDA Panel’s Surprising Vote on Peptides: What It Means for Patients and Providers
In late July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) shocked many observers by narrowly recommending six peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—for potential inclusion on the 503A Bulks List. This decision went against FDA scientists, who had advised rejecting all seven peptides under review. The only outright rejection was emideltide, also known […]
FDA Panel’s Surprising Vote on Peptides: What It Means for Patients and Providers Read More »
